Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer breakthrough: chemo spares Low-Risk patients

NCT ID NCT07250360

Knowledge-focused Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study involved over 2,000 people with early-stage non-squamous lung cancer who had surgery. Researchers wanted to see if adding chemotherapy after surgery helped prevent the cancer from coming back. They found that chemotherapy only improved survival for patients with high-risk features, not for everyone. The team also created a computer tool to help doctors decide who should get chemo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,072 people

The number who actually took part.

Started

Jan 2015

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with non-squamous NSCLC from four participating hospitals

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients must have histologically confirmed non-squamous NSCLC 2. Patients must be ≥18 years of age at the time of diagnosis 3. Pathological stage I disease (T1-2N0M0) according to the AJCC 8th edition (specify if applicable) 4. Patients must have undergone complete surgical resection (R0) with systematic lymph node dissection 5. Surgery performed between January 1, 2015 and December 31, 2019 Exclusion Criteria: 1. Prior history of malignant tumors or presence of synchronous other primary malignancy 2. Multiple primary lung cancers diagnosed at baseline 3. Receipt of any neoadjuvant chemotherapy, radiotherapy, or targeted therapy 4. Perioperative death occurring within 30 days after surgery 5. Incomplete or missing clinical or pathological information 6. Loss to follow-up before the first scheduled surveillance assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer stage I are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer stage I

More trials for these conditions

Other studies related to the condition(s) this trial covers.